They look exactly the same. It easily raises the question, isn’t it possible to combine them into one entity? Apparently, the desktop model has slightly better quality images than the portable one (after all, even a professional photographer doesn’t move anywhere without a tripod). The portable one is advertised especially for remote areas. (Where money is tighter). Sorry for the grumbling 
1 Like
I wouldn’t be particularly surprised if Topcon were to make an offer for Optomed at some point. Topcon doesn’t have its own handheld camera, the companies share partners, and oculomics is at the core of their strategy. That’s a very strong combination as the screening market opens up more significantly.
23 Likes
I agree that Optomed would perfectly complement Topcon’s product portfolio and is the most likely candidate to make an offer. One driver, of course, is the FDA-approved handheld camera with an AI solution, but also a strong patent portfolio and technological expertise. In addition, Topcon’s ready global distribution network would immediately unlock enormous worldwide potential and the opportunity to expand into developing markets with an affordable portable screening solution. And certainly, major competitors are thinking about how all this would affect market dynamics if another big player were to acquire Optomed. Canon or even Zeiss could be in line, as Optomed’s price is still quite moderate compared to the future market. However, let’s hope that Optomed’s own strengths are sufficient for global conquest and that we get a new star on the Helsinki Stock Exchange.
13 Likes
So, visiting with the right resident?
33 Likes
This means, if true, that the stock is cheap. No sign of hype or FOMO.
Now we at least know that in the coming weeks we’ll get the new camera announcement, and at least based on their statements, the company considers it a very significant step.
9 Likes
That doesn’t mean it’s cheap. Rather, it means it’s not interesting in light of its recent history and figures. From the technical figures, you can see that a loss-making company cannot be called cheap. For over 10 consecutive years, it has operated with negative figures and burned through cash. The company’s value is currently more a matter of faith, and that reflects interest. More concrete evidence and less noise are now needed to see if the current trend continues or changes.
10 Likes
Healthy Heart Africa is indeed a project of a truly significant scale. No wonder then that even humble Himberg dared to mention aloud the potential of the African market. What is the Healthy Heart Africa programme?
Apparently, in that project, they screen over 10 million Africans per year. It would certainly be wonderful if eyes were also imaged with Aurora at the same time.
https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15587
26 Likes
https://www.nmpa.gov.cn/zwfw/sdxx/sdxxylqx/qxpjfb/20250514152046169.html?type=pc&m=
Optomed can be found on line 68. It has received some kind of permit for a fundus camera in China, but I have to admit that I can’t make any sense of it myself, which is why I’m linking it here. Maybe someone else will find something interesting.
5 Likes
It seems to be the Optomed Aurora permit. As I recall, in China, permits must be renewed every 5 years, and the previous one was in 2020.
7 Likes
You are right. Aurora was granted a permit on 29.10.2020, which would have expired on 28.10.2025. There was nothing special about this, but thanks for the help.
5 Likes
“…scale our strategic partnerships…”
20 Likes
In total, there appear to be 7 open positions in the United States, including, for example, two Regional Sales Managers, and four positions also open in Tal Alv, where they are looking for, for example, the same business director as in the United States, and additionally an AI researcher. And if Optomed also already had plans to hire more for their sales team, then based on this, one could assume that sales have started to pick up with AI solutions across the pond.
25 Likes
Is anyone aware of any good event where a product launch could be made? When searching for events on Google, there are surprisingly many still left for the remainder of Q2, and different sources even list different events, so there would certainly be opportunities for presentations. Should the device even be presented at an event focused solely on ophthalmology, or should we look for a medical technology event?
For example, such listings of important events can be found.
4 Likes
First, this comes to mind
https://egsmembersmeeting.org/
But on Optomed’s own pages there would be
Meetings - EASDEC (they are indeed crappy pages ..straight from some 2000s)
I myself think that they don’t want to make a publication before they get a sales permit in the US. Or at least that it would be as close as possible to coming. They don’t want to make a paper publication and they don’t want to spoil the end of Q2.
1 Like
It is definitely not coming to the US market yet; it has specifically been stated that it will be for selected markets where it does not cannibalize existing products. Also, no investor communication-related quarterly optimization is practiced in this company, nor is such a thing combined with any trade show.
So it will come as soon as the whole thing is ready. I’m guessing some limited European launch, with an algorithm or two included right away in the package.
13 Likes
Francesca Logan of Toku Eyes shares updates on Toku. The ongoing cardio trial is in its final stages, and after that, a similar trial will begin with Optomed’s camera. Toku has recently apparently entered CVS pharmacies with its Bioage product.
20 Likes
Following the steps of these companies in the field, it’s quite clear that various types of AI-assisted diagnostic screening from the fundus is a very large emerging market area.
Regarding Optomed, the essential questions are 1) how well it can produce a relevant piece for the value creation chains, 2) what the competitive situation is and thus the margin level in Optomed’s piece, and 3) how the company succeeds in turning the opportunity into a business.
I am following with interest and with a reasonable number of shares.
14 Likes
How do you envision the revenue model in this SaaS business for a camera manufacturer? Himberg says in Kinnunen’s Q1 interview that “…the attractiveness of this whole platform comes from how many of these algorithms are running in parallel…” (after this, he talks about the situation in the USA where only one algorithm has been approved so far and hopes for more approvals) (addition: the discussion also covers other markets where more have been approved).
Question: when Himberg apparently has in mind a situation where one customer has a camera with which the said customer performs several screenings, perhaps even as a bundle for one patient from the same image, how might the camera company bill for these screenings? Is it roughly 50/50 for each algorithm with the AI producer, as is currently the case with AEYE health, or will there be a volume discount for the camera company, which might not make sense because the algorithm companies are separate.
Comparison: Apple owns a platform where several “algorithm (app) manufacturers and sellers” operate, taking 30% of everyone’s business.
Himberg consistently uses the term “platform,” not “camera.”
Is there a possibility here for multiple billing for a single product, in line with platform dynamics, and corresponding revenue?
12 Likes
Hi, new here following the company OPTOMED, when is the launch of the new LUMO camera expected and what is the estimated impact on the share price?
3 Likes